This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Q2 FY27 consolidated: revenue Rs 640.22 cr vs Rs 578.96 cr year ago; net profit Rs 22.22 cr vs loss
UNICHEMLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.1 pts less than Nifty Microcap 250 and 1.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
For the quarter ended 30 September 2026, consolidated revenue was Rs 640.22 crore versus Rs 578.96 crore year ago, and net profit was Rs 22.22 crore versus a Rs 11.89 crore loss. An exceptional Rs 24.26 crore claims provision reduced profit. Standalone revenue was Rs 401.90 crore versus Rs 356.90 crore year ago, and net profit Rs 1.49 crore versus a Rs 39.93 crore loss. Half-year consolidated operating cash flow was negative Rs 68.07 crore.
Revenue growth and a return to profit help, but the exceptional claims provision and negative half-year operating cash flow may cap stock gains.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹640.2 Cr | ₹579.0 Cr | +10.6% |
| Operating profit | ₹36.26 Cr | ₹26.47 Cr | +37.0% |
| Profit after tax | ₹22.22 Cr | −₹11.89 Cr | turned positive |
| EBITDA margin | 7.8% | 1.4% | +6.5 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.